Biogen Inc. (BIIB)
Pre-market:
| Previous close | 216.13 |
| Open | 217.99 |
| Bid | 213.41 x 100 |
| Ask | 213.52 x 100 |
| Day's range | 213.14 - 218.46 |
| 52-week range | 189.44 - 319.76 |
| Volume | |
| Avg. volume | 1,301,414 |
| Market cap | 31.086B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 26.66 |
| EPS (TTM) | 8.01 |
| Earnings date | 23 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 284.76 |
GlobeNewswireBiogen Reports Progress on Corporate Responsibility Priorities
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing progress on the company’s commitment to making responsible business decisions in the best interests of all its stakeholders. “As we reflect on the past year and set our sights on the path ahead, I am truly inspired by the prog
ZacksAre You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investor's Business DailyIs Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Eli Lilly reported strong sales of weight-loss drug Zepbound in the first quarter. Is Eli Lilly stock a buy?
